» Articles » PMID: 17828300

Elevated Mdm2 Expression Induces Chromosomal Instability and Confers a Survival and Growth Advantage to B Cells

Overview
Journal Oncogene
Date 2007 Sep 11
PMID 17828300
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Mdm2, a regulator of the p53 tumor suppressor, is frequently overexpressed in lymphomas, including lymphomas that have inactivated p53. However, the biological consequences of Mdm2 overexpression in lymphocytes are not fully resolved. Here, we report that increased expression of Mdm2 in B cells augmented proliferation and reduced susceptibility to p53-dependent apoptosis, which was due to inhibition of p53 and suppression of p21 expression. Notably, developing and mature B cells from Mdm2 transgenic mice had an increased frequency of chromosomal/chromatid breaks and/or aneuploidy. This Mdm2-mediated genome instability occurred at a similar frequency as that in B cells overexpressing the oncogene c-Myc, but the chromosomal instability was not further enhanced when Mdm2 and c-Myc were overexpressed together. Elevated Mdm2 expression alone increased the occurrence of B-cell transformation in vivo and cooperated with c-Myc overexpression, resulting in an acceleration of B-cell lymphomagenesis. In addition, the frequency of p53 mutations was reduced, but not eliminated, in lymphomas arising in Mdm2/Emu-myc double transgenic mice. Therefore, increased Mdm2 expression facilitated B-cell lymphomagenesis, in part, through regulation of p53 by altering B-cell proliferation and susceptibility to apoptosis, and by inducing chromosomal instability.

Citing Articles

Long noncoding RNA, is associated with aneuploidy and its magnitude of expression level is dependent on P53 status.

Malakar P Front Cell Dev Biol. 2025; 12:1410308.

PMID: 39763585 PMC: 11702365. DOI: 10.3389/fcell.2024.1410308.


MDM2 inhibitors in cancer immunotherapy: Current status and perspective.

Zeng Q, Zeng S, Dai X, Ding Y, Huang C, Ruan R Genes Dis. 2024; 11(6):101279.

PMID: 39263534 PMC: 11388719. DOI: 10.1016/j.gendis.2024.101279.


MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.

Wang W, Albadari N, Du Y, Fowler J, Sang H, Xian W Pharmacol Rev. 2024; 76(3):414-453.

PMID: 38697854 PMC: 11068841. DOI: 10.1124/pharmrev.123.001026.


Machine Learning Algorithms Identify Target Genes and the Molecular Mechanism of Matrine against Diffuse Large B-cell Lymphoma.

Zhu Y, Ning Z, Li X, Lin Z Curr Comput Aided Drug Des. 2023; 20(6):847-859.

PMID: 37605410 DOI: 10.2174/1573409920666230821102806.


Targeting AKT with costunolide suppresses the growth of colorectal cancer cells and induces apoptosis in vitro and in vivo.

Huang H, Park S, Zhang H, Park S, Kwon W, Kim E J Exp Clin Cancer Res. 2021; 40(1):114.

PMID: 33785035 PMC: 8010944. DOI: 10.1186/s13046-021-01895-w.